Understanding "Each Unique Test" in Medicare Coding Requirements
In Medicare coding requirements, "each unique test" refers to each distinct analytical procedure or assay performed, where each individual test component—such as a specific PCR assay for a particular pathogen—must be separately identified and coded, even when multiple tests are run from the same specimen. 1
What Constitutes a "Unique Test"
The concept is most clearly illustrated in molecular diagnostics, where Medicare Administrative Contractors (MACs) require specific documentation for each analytical component:
- Each individual assay counts as a unique test, even when performed simultaneously from a single sample
- For example, if you run influenza PCR, Bordetella PCR, and SARS-CoV-2 PCR from one respiratory specimen on a pediatric patient with cough and fever, this represents three unique tests 1
- Each potential combination of assays must be submitted separately for coverage consideration 1
Key Distinction: Tests vs. Procedures
The current coding system creates complexity because it focuses on procedures involved in performing tests (called "stacked coding") rather than the individual molecular tests themselves 2:
- Multiple independent standalone assays can be considered a panel when performed together
- However, for billing purposes, each component assay within that panel may need separate documentation
- This is why the same molecular testing can be coded differently by different laboratories, resulting in varied reimbursement rates 2
Practical Implications for Coding
When billing Medicare, you must:
- Document each analytical service performed (cell lysis, nucleic acid extraction, amplification, detection, interpretation) 2
- Link each unique test to its own diagnostic code (ICD code) 3
- Generate separate interpretive reports when multiple test types are performed (e.g., cardiac and pulmonary measurements require distinct reports) 3
Common Pitfall to Avoid
Do not assume that running multiple assays as a "panel" means you can bill it as a single test. MACs like Palmetto MolDx specifically require that each potential combination of assays be submitted for coverage consideration as if they were multiple independent tests 1. Failing to properly identify each unique test component can result in claim denials or unexpected patient charges.
Context for Multiplex Panels
This requirement becomes particularly important for broad multiplex molecular panels, where:
- Some MACs limit reimbursement when certain types of tests are ordered on the same day for a single patient 1
- Each component of the panel may require separate clinical validity and utility documentation 1
- The coding must clearly communicate which specific tests were actually performed, not just that "a respiratory panel" was run 2